Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Leukemogenic AML1-ETO-targeted proteins identified
October 25th, 2006
Leukemogenic AML1-ETO-targeted proteins have been identified. "AML1-ETO is a leukemogenic fusion protein generated by chromosomal translocation t(8; 21) (q22; q22), one of the most frequent chromosomal abnormalities in acute myeloid leukemia. The fusion protein has been shown to present dichotomous functions on leukemic cells: growth arrest versus differentiation block. "However, their precise molecular mechanisms are not completely clear. In this work, we try to explore potential AML1-ETO-targeted proteins through comparing two-dimensional electrophoresis (2DE)-based global protein expression profiles of leukemic U937 cells with and without...
Source: Biotech Week (2006-10-25)
|
